Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the 10 Stocks Investors Are Buying Now. Corcept Therapeutics rallied for a second day on Wednesday, soaring 19.66 percent to finish at $40.47 apiece, as investors snapped up shares after securing the green light of the Food and Drug Administration (FDA) to sell its ovarian cancer treatment, Lifyorli. In an updated report, Corcept Therapeutics Inc. (NASDAQ:CORT) said that the approval was based on the success of its clinical trial, which enrolled 381 patie ...

Corcept Therapeutics (NASDAQ: CORT) took its investors for quite a ride on Hump Day. The commercial-stage biotech earned its latest nod from a regulator that afternoon and, not surprisingly, its shares leaped skyward on the news. By the end of the day, they had risen by almost 20% in value. The FDA says yes to Lifyorli Corcept announced that the U.S. Food and Drug Administration (FDA) approved its Lifyorli, in combination with the chemotherapy drug nab-paclitaxel, for the treatment of the platinum-resista ...

公司核心事件：新药获批与市场反应 - Corcept Therapeutics公司股价在消息公布后飙升超过32%，达到近两个月高点[1] - 此次获批比预期时间提前了三个月[4] 获批药物详情 - 美国食品药品监督管理局批准了relacorilant（商品名Lifyorli）与化疗药物nab-paclitaxel联合使用[2] - 该疗法适用于铂类耐药的上皮性卵巢癌成人患者，这类癌症通常在铂类化疗后约六个月内复发或进展[2] - Lifyorli通过阻断体内皮质醇相关的应激信号发挥作用，该机制可使癌细胞对化疗更敏感[2] 临床试验数据 - 批准基于一项涉及381名患者的后期试验[3] - 数据显示，接受联合治疗的患者中位生存期为16个月，而仅接受化疗的患者为11.9个月[3] - 美国食品药品监督管理局建议患者在每次输注nab-paclitaxel的前一天、当天和后一天服用150毫克该药物[3] 药物销售前景与历史背景 - 瑞银分析师估计该药物的峰值销售额约为5.5亿美元[4] - 2023年12月，美国食品药品监督管理局曾拒绝批准relacorilant用于治疗库欣综合征相关的高血压，导致公司股价暴跌约50%[5] - 此前拒绝的原因是药物未能优于安慰剂，并引发了潜在的肝损伤担忧[5] 药物使用警告 - 该治疗带有白细胞计数低、严重感染、肾上腺功能不全以及对未出生婴儿潜在危害的警告[4] - 不应用于依赖类固醇药物生存的患者[4] - 分析师指出，对使用类固醇药物的患者的禁忌症可能是一个障碍[4]